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Hypoxia Inducible FactorRegulation of both systemic and cellular iron homeostasis requires the capacity to sense iron levels and
appropriately modify the expression of iron metabolism genes. These responses are coordinated through
the efforts of several key regulatory factors including F-box and Leucine-rich Repeat Protein 5 (FBXL5),
Iron Regulatory Proteins (IRPs), Hypoxia Inducible Factor (HIF), and ferroportin. Notably, the stability of
each of these proteins is regulated in response to iron. Recent discoveries have greatly advanced our under-
standing of the molecular mechanisms governing iron-sensing and protein degradation within these path-
ways. It has become clear that iron's privileged roles in both enzyme catalysis and protein structure
contribute to its regulation of protein stability. Moreover, these multiple pathways intersect with one another
in larger regulatory networks to maintain iron homeostasis. This article is part of a Special Issue entitled: Cell
Biology of Metals.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Due to the abundance and chemical properties of iron, life on Earth
evolved to depend on this transition metal [1]. Nearly every prokaryote
and all eukaryotes require iron for their viability [2]. On account of iron's
ease in donating and accepting electrons, iron is employed by a variety
of proteins to carry out oxidation–reduction reactions [3]. Iron-utilizing
proteins are necessary for critical biological processes such as the trans-
port and storage of oxygen, deoxyribonucleotide synthesis, chromatin
regulation, and oxidative phosphorylation [4]. Though required for sus-
taining life, iron can have deleterious consequenceswhen present in ex-
cess. Copious free iron generates radical species through Fenton
chemistry, causing oxidative damage to proteins, nucleic acids, and
lipids [5]. Consequently, the acquisition, export, usage, and storage of
iron are regulated in most organisms in order to maintain iron homeo-
stasis [6]. Aberrant iron homeostasis is the principal pathogenic factor
in multiple human diseases. Due to the high iron demand of red blood
cells, iron deﬁciency causes anemia in approximately a billion individ-
uals worldwide [3]. At the other end of the iron-related disorders spec-
trum is hemochromatosis, a disease of iron overload, that can lead to
heart failure, diabetes, and cirrhosis [6]. Thus, the challenge for humans
is to maintain sufﬁcient iron levels to sustain life while avoiding the po-
tentially detrimental effects of excess iron [3]. Due to their multicellular
nature and complex tissue organization, mammals regulate iron ho-
meostasis at both the systemic and cellular levels. In contrast to bacteria
and yeast that largely regulate iron metabolism genes at the level ofiology of Metals.
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l rights reserved.transcription [7–9], multiple posttranscriptional mechanisms are criti-
cal for maintaining mammalian iron homeostasis [3–6]. In particular,
several key regulatory factors differentially accumulate in response to
changes in iron availability as a consequence of dynamic proteolysis.
Our understanding of the mechanisms underlying iron-sensing and
regulated protein degradation has greatly advanced during the last sev-
eral years.
2. Iron-responsive regulation of ferroportin proteolysis
The iron export protein ferroportin is an essential regulator of sys-
temic iron homeostasis (reviewed in this issue of BBA-Molecular Cell
Research). Following uptake dietary iron can be stored in the cytosol
or efﬂuxed into the plasma via the actions of ferroportin, a membrane
bound dimer localized to the basolateral side of intestinal epithelial
cells. Ferroportin is also expressed on the cell surface of hepatocytes
and macrophages where it plays a key role in releasing stored iron
and iron recycled from phagocytosed erythrocytes, respectively [4].
Ferroportin stability is posttranslationally regulated by the hormone
hepcidin, a circulating member of the defensin family of peptides
that is secreted primarily by the liver [10]. When serum iron levels
are sufﬁcient to satisfy systemic demand, the gene encoding hepcidin
(HAMP) is upregulated and hepcidin is secreted into the blood where
it binds ferroportin [11]. This interaction induces a structural change
within ferroportin, promoting the recruitment of the Jak2 kinase
and its subsequent phosphorylation [12]. Phosphorylated ferroportin
is internalized and ubiquitinated by the E3 ligase Nedd4-2 [13]. Ubi-
quitinated ferroportin is processed through the endosome and subse-
quently delivered to the lysosome where it is degraded (Fig. 1),
diminishing iron export to effectively reduce serum iron levels
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temic demand for iron is high, ultimately stabilizing ferroportin and
increasing iron efﬂux into the serum [15–17].
Ferroportin has also been recently shown to be directly regulated
by iron via a hepcidin-independent mechanism in cultured cells [13].
When cytosolic iron levels are depleted, ferroportin is believed to un-
dergo a conformational change due to the lack of iron binding and
transport. This alternate conformation renders ferroportin susceptible
to ubiquitination, which is dependent on Nedd4-2 and its interacting
partner Nfdip-1. Following Nedd4-2/Nfdip-1 dependent ubiquitina-
tion, ferroportin is internalized and ostensibly degraded in the lyso-
some (Fig. 1). Interestingly, a Caenorhabditis elegans ferroportin
homolog undergoes iron limiting internalization and degradation,
suggesting that this mechanism of controlling iron homeostasis evo-
lutionarily precedes hepcidin, which is only expressed in vertebrates
[13]. In this context, ferroportin behaves as an iron sensor whose en-
suing conformational change contributes to the regulation of iron
homeostasis.
3. Hypoxia inducible factor and iron homeostasis
Many cellular processes such as oxidative phosphorylation and
chromatin remodeling are dependent on both iron and O2 [18,19].
Therefore, it is not surprising that cells have evolved to coordinate
the regulation of iron and oxygen metabolism. Similar to iron, O2
levels must be maintained in an optimal range that is sufﬁcient for
critical cellular processes, while minimizing oxidative damage gener-
ated in the presence of excess oxygen [20]. In mammalian cells, oxy-
gen homeostasis is maintained in part by the dimeric transcription
factor Hypoxia Inducible Factor (HIF). HIF contains a constitutively
expressed β-subunit and a regulated α-subunit. HIF-α is preferential-
ly degraded under normoxic conditions, precluding formation of an
active HIF heterodimer. Under hypoxic conditions the α-subunit is
stabilized, allowing its interaction with the β-subunit and subsequent
induction of an assortment of genes to elicit adaptive responses to
low O2 availability [21,22].
HIF-α is degraded when O2 is plentiful via the ubiquitin–protea-
some system (UPS) [23,24]. In this regulatory system a trio of factors,
designated E1, E2, and E3, catalyze the transfer of polyubiquitinchains to proteins. Polyubiquitinated proteins are degraded in the
macromolecular proteasome complex in order to maintain protein
homeostasis [25,26]. Recognition of HIF-α under normoxic conditions
by the product of the von Hippel Lindau tumor suppressor gene
(pVHL), a component of the E3 ubiquitin ligase responsible for its
polyubiquitination, requires the action of a family of HIF prolyl hy-
droxylases. As their name suggests, these enzymes hydroxylate pro-
line residues on HIF-α in an O2- and iron-dependent manner
[27–30]. These metabolic requirements are conferred in part by the
role of iron in facilitating the binding and activation of the O2 sub-
strate consumed during hydroxylation (Fig. 2). As a result, depletion
of cellular iron stores upon addition of iron chelators abolishes hy-
droxylase activity and promotes HIF-α stabilization [20]. Increased
stabilization of HIF-α is also observed in mice maintained on a low
iron diet [31]. Due to the requirement of iron for their activity, it
has been hypothesized that these hydroxylases may function as phys-
iological iron sensors [18,20,32]. Moreover, it is becoming increasing-
ly evident that HIF itself plays a direct role in iron homeostasis as a
number of HIF target genes mediate iron metabolism [31,33–41].
4. Iron responsive protein degradation mediates cellular iron
homeostasis
Iron Regulatory Proteins 1 and 2 (IRP1 and 2) bind RNA stem loop
structures, known as iron responsive elements (IREs), found in a co-
hort of genes involved in iron uptake, storage, and utilization
(reviewed in this issue of BBA-Molecular Cell Research). This IRE/
IRP system has emerged as the central regulatory pathway for the
maintenance of mammalian cellular iron homeostasis [2]. The quin-
tessential IRE-containing genes are those encoding ferritin and trans-
ferrin receptor 1 (TfR1). TfR1 is largely responsible for iron uptake
from the serum while ferritin stores and sequesters excess cellular
iron [42]. IRP binding to the IRE on the 5′ untranslated region (UTR)
of ferritin inhibits ribosomal binding and decreases ferritin transla-
tion. In the case of TfR1, IRP binding to multiple IREs within its 3′
UTR prevents endonucleolytic mRNA degradation thereby increasing
expression. However, IRPs fail to interact with IREs under iron replete
conditions, promoting ferritin translation and reduced TfR1 mRNA
stability. Through effects on these and other genes, the IRE/IRP
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Fig. 2. Proteolytic regulation of HIF requires iron. (A) The HIF prolyl hydroxylase active site utilizes iron to bind dioxygen in order to hydroxylate proline residues on HIF-α. (B)
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diating iron metabolism in order to maintain cellular iron
homeostasis.
The IRE binding activities of the two IRPs are regulated by distinct
mechanisms. When bioavailable iron is abundant, IRP1 assembles an
iron–sulfur (Fe–S) cluster (holo-IRP1) and functions as a cytosolic aconi-
tase enzyme, interconverting two intermediates of the TCA cycle, citrate
and isocitrate [43,44]. Apo-IRP1, enriched in cells where iron levels are
low and Fe-S cluster synthesis is presumably compromised, is competent
to bind IREs in theUTRs of genes such as ferritin andTfR1. In contrast, IRP2
is regulated at the posttranslational level via the UPS. IRP2 protein levels
decrease substantially in cells treated with iron due to polyubiquitination
of the protein with concomitant proteasomal degradation. Under iron
limiting conditions however, the IRP2 protein is stabilized and preferen-
tially accumulates, enabling its interaction with IRE-containing mRNAs
[45–47]. In addition to being regulated by bioavailable iron levels, IRP2
is regulated in an O2-dependent manner. Under normoxic conditions,
IRP2 has a half-life of ~6 hwhich increases to greater than 12 h in hypoxic
cells [48].
The physiological importance of both IRPs is reﬂected by the
embryonic-lethal phenotype observed for global Irp1−/−Irp2−/− mice
[49]. IRP2 null mice display inappropriate regulation of IRE-containing
genes in many tissues, mild neurodegeneration, and microcytic anemia
[50–52]. In comparison to IRP2 knockout mice, misregulation of iron
metabolism only occurs in brown fat and kidneys of Irp1−/− mice
while no other overt phenotypeswere reported [51]. These data suggest
that IRP2 may play a larger role in regulating iron homeostasis in vivo.
While it has been known for decades that IRP1 can be regulated as
a function of its Fe–S cluster binding activity, delineation of the mech-
anisms controlling IRP2 regulation has proven more elusive [3,53,54].
Speciﬁcally, the E3 ubiquitin ligase that targets IRP2 for degradation
and the mechanisms cells use to sense iron levels and correlate
changes of this metabolite to differences in IRP2 stability have only
recently been revealed.
5. FBXL5 is an iron-sensing E3 ubiquitin ligase that regulates iron
homeostasis
An increased understanding of how the UPS controls the mainte-
nance of iron homeostasis via regulation of IRP2 came with the discov-
ery of an IRP2 E3 ubiquitin ligase. This E3 ligase, F-box and Leucine-rich
Repeat Protein 5 (FBXL5), was independently identiﬁed by two labora-
tories [55,56]. Using a proteomics approach, IRP2 was identiﬁed as an
interacting partner of a substrate-trapping FBXL5 variant [56]. In an al-
ternative approach, FBXL5 was identiﬁed in an RNAi screen for regula-
tors of iron-dependent IRP2 degradation [55]. FBXL5 is a member of
the protein family deﬁned by a conserved ~40–50 amino acid F-box do-
main [57]. F-box proteins assemble into Skp1/Cul1/F-box (SCF) E3 ubi-
quitin ligase complexes composed of the scaffolding proteins CUL1,
RBX1, and SKP1. SKP1 recruits the F-box containing subunit of the E3 li-
gase complex. The function of the F-box protein is critical as its employsadditional domains to tether substrates to the multimeric SCF complex
for polyubiquitination. RBX1 is a ring-box protein that binds an activat-
ed E2 conjugating enzyme, which transfers ubiquitin to the SCF com-
plex target protein [25,58].
Loss of FBXL5 expression in human cells causes inappropriate ac-
cumulation of IRP2 with concomitant misregulation of IRE containing
genes under iron replete conditions [55,56]. FBXL5 interacts with
IRP2 in human cells and recombinant SCFFBXL5 polyubiquitinates
IRP2 in vitro [55,56]. Taken together, these observations suggest
that FBXL5 is a bona ﬁde IRP2 E3 ligase, required for proper regulation
and maintenance of cellular iron homeostasis. IRP1 can similarly be
regulated via FBXL5 in an iron-dependent fashion when Fe-S cluster
assembly is otherwise compromised, although the physiological rele-
vance of this proteolytic regulation is unknown [55,56,59,60].
Intriguingly, FBXL5 is regulated in a reciprocal fashion to IRP2. FBXL5
accumulates under conditions of excess iron, while it is destabilized
when either iron or O2 becomes limiting [55,56]. Both iron- and
oxygen-dependent control of FBXL5's stability are mediated through
its N terminus, predicted to encode an iron-binding hemerythrin-like
domain [55,56]. Hemerythrin (Hr) domains from marine invertebrates
and bacteria are well characterized though no vertebrate Hr domains
had previously been identiﬁed [61–67]. In invertebrates, Hr containing
proteins frequently function as O2 transport and storage proteins simi-
lar to the mammalian proteins hemoglobin and myoglobin [68]. In ad-
dition to these roles, it has been postulated that Hr proteins function
as iron and/or O2 sensors [63,69,70]. Canonical Hr domains are charac-
terized by a helical bundle fold containing four α helices and an O2-
binding diiron center. The binuclear iron center is typically ligated by
seven amino acids comprised of ﬁve histidines, one aspartic acid, and
one glutamic acid. The ﬁrst iron atom (Fe1) of the diiron center is coor-
dinated by three histidines and the second iron (Fe2) is coordinated by
two histidines with the acidic residues bridging both atoms. The diiron
center is also bridged by a solvent-derived μ-hydroxo group in the
deoxy state (Fig. 3A). Hr domains can reversibly bind dioxygen at the
Fe2 site. Bound O2 is reduced and the ensuing peroxide species forms
a hydrogen bond with the resultant μ-oxo group and is further stabi-
lized by hydrophobic residues lining the binding pocket [68,71,72].
Recently, X-ray crystallography has conﬁrmed that the N terminus
of human FBXL5 contains a hemerythrin-like domain [73]. Analogous
to bacterial and invertebrate Hr domains, the FBXL5 Hr domain fea-
tures a diiron center assembled within an up-down α-helical bundle
supported by an atypical ﬁfth helix. Moreover, the helical bundle is
substantially longer (~58 Å) in FBXL5 than in previously character-
ized domains (~40–50 Å) [61,63] (Fig. 4). FBXL5's diiron center also
differs from canonical Hrs by employing only four coordinating histi-
dines. In place of the ﬁfth histidine ligating Fe1, the FBXL5 Hr employs
a glutamic acid that appears to form an unprecedented hydrogen
bond with both Fe1 and the μ-oxygen species (Fig. 3B). Another dis-
tinctive aspect of the FBXL5 Hr domain is the absence of observable
O2 binding at the diiron center despite crystallization in the presence
of ambient oxygen [73]. Stopped-ﬂow spectroscopy also suggests the
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drophobic pocket juxtaposed to the diiron center that resembles ca-
nonical Hr domains, the dimensions of the FBXL5 pocket are much
smaller and therefore dioxygen-binding may not be physically possi-
ble in this uncommon vertebrate Hr.
Recent molecular approaches have provided insights into the
mechanisms controlling FBXL5 regulation [73]. Mutation of the iron-
ligating residues in the Hr domain results in constitutive destabiliza-
tion of FBXL5 demonstrating that Fe binding is necessary for proper
regulation of FBXL5. Under iron replete conditions when the protein
accumulates at high levels, FBXL5 exhibits low levels of polyubiquiti-
nation. Conversely, when iron is limiting, FBXL5 displays pronounced
polyubiquitination and subsequent degradation that is dependent on
a functional E1 ubiquitin-activating enzyme and the proteasome.
Moreover, residues 77–81 within the Hr domain appear to comprise
a part of a regulatory element, or degron, mediating FBXL5's differen-
tial stability. Taken together, these multiple lines of evidence suggest
a model in which FBXL5's N-terminal Hr domain senses iron and reg-
ulates FBXL5 stability (Fig. 5). According to this model, when intracel-
lular iron levels are abundant the Hr domain binds iron and adopts a
conformation in which its degron is less accessible. Degron sequestra-
tion results in FBXL5 stabilization, formation of an SCFFBXL5 E3 ligase
complex, and polyubiquitination of IRP2 with subsequent proteasomalHemerythrin FBXL5
BA
Fig. 4. Structure of the FBXL5 Hr domain compared to the classical domain. Ribbon rep-
resentations of the Hr domain from T. dyscritum (A; PDB code 1HMD) and the
hemerythrin-like domain from H. sapien FBXL5 (B; PDB code 3V5Y).degradation. Conversely, when bioavailable iron levels are low the
FBXL5 Hr domain is unable to form a diiron center, resulting in a struc-
tural change that exposes the regulatory element targeting FBXL5 for
polyubiquitination and degradation. Iron-dependent regulation of
FBXL5 is predicted to be critical as it controls IRP2 expression levels,
which in turn regulates key iron homeostasis genes. Thus FBXL5, via
its Hr domain, enables cells to gauge bioavailable iron levels and control
IRP2 accumulation accordingly, forming a tightly regulated circuit in the
maintenance of iron homeostasis.
The ﬁnding that FBXL5's stability is controlled via an iron-binding
regulatory switch in its Hr domain is particularly signiﬁcant. This type
of ligand-dependent regulation has been observed with multiple
F-box proteins in plants and algae. For example, binding of jasmonate
to the plant F-box protein COIl, enhances the interaction between
COI1 and JAZ proteins [74,75]. In red algae, Fbx3 binds Mg-
protoporphyrin IX which negatively regulates binding to its substrate
cyclin 1 [76]. However, FBXL5 is the ﬁrst example of a metazoan F-box
protein to function in an analogous ligand-regulated manner.
As with ferroportin, iron binding to the Hr domain is postulated to
induce a conformational change that increases ubiquitination and
degradation of FBXL5. Such regulation is also reminiscent of the
yeast ER protein Pca1, which functions as an ATPase and exporter of
the toxic metal cadmium. In the absence of cadmium, a degron is
exposed and Pca1 is targeted for proteasomal degradation. However
when cadmium levels are high, Pca1 binds cadmium and elicits a
structural change purported to mask a degron and spare the protein
from degradation. Upon cadmium binding, the Pca1–Cd complex
may be excreted from the cell in order to reduce cadmium levels
[77]. Both FBXL5's and Pca1's stabilities are dependent on binding of
their cognate metals to control degron accessibility. Moreover, both
proteins functions as sensors to maintain homeostasis of their respec-
tive metals.
While these results indicate that FBXL5 is necessary for maintain-
ing proper iron homeostasis in cultured cells [55,56], they do not
address the role of SCFFBXL5 in regulating iron homeostasis in vivo. A
forward genetics screen in mice generated a FBXL5 mutant strain
where methionine 127 had been changed to lysine [78]. As shown
in the FBXL5 Hr structure, M127 is positioned very closely (~4 Å) to
both the bridging μ-oxo atom and Fe2 [73]. Mutation of the basic
lysine residue likely interferes with assembly of the diiron center,
constitutively destabilizing FBXL5. Mice homozygous for this muta-
tion display embryonic lethality, suggesting that a functional FBXL5
is required for murine development [78].
Using a targeted approach, it was recently reported that global disrup-
tion of the FBXL5 gene in mice results in death at E8.5 [79]. Importantly,
these Fbxl5−/− embryos feature aberrant iron accumulation and in-
creased oxidative stress that are likely responsible for lethality. Consistent
with FBXL5's importance for IRE-containing gene regulation, Fbxl5−/−
embryos have elevated levels of TfR1 mRNA. To demonstrate that misre-
gulation of IRE containing genes due to uncontrolled IRP2 accumulation
causes lethality in Fbxl5−/− embryos, Fbxl5+/−Irp2+/− mice were
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neous loss of IRP2 rescues the FBXL5 null phenotype as these mice devel-
op normally and are fertile, indicating that control of IRP2 expression via
FBXL5 is required for the maintenance of iron homeostasis and viability
during murine development. To investigate the function of FBXL5 in
adult mice, liver speciﬁc knockout mice were also generated [79]. These
mice displayed increased liver iron accumulation and elevated hepatic
IRP2 and TfR1 protein levels. Additionally, mice lacking FBXL5 expression
in the liver manifested decreased hepcidin expression and increased
serum iron levels compared to wild-type littermates. When fed a high
iron diet, the majority of these mice accumulate even more iron within
the liver in conjunction with increased oxidative stress and steatosis.
Though no other organs were observed with iron overload, most of
these mice die within one day due to the ensuing liver failure [79]. To-
gether, thesedata indicate that FBXL5 expression is required formaintain-
ing both cellular and systemic iron homeostasis in vivo.
The discovery that FBXL5 plays an integral role in maintaining iron
homeostasis represents an important step in the metals biology ﬁeld.
However, FBXL5 research is still in its infancy and much remains to be
resolved. Current data indicates that IRP2 and apo-IRP1 are SCFFBXL5
substrates [55,56,79] though p150Glued, a protein involved in vesicular
transport, has also been reported to be a FBXL5 substrate [80]. A key
step in understanding FBXL5's functions will be to delineate its com-
plete repertoire of substrates. Due to the iron-responsiveness of
FBXL5, future studies identifying additional FBXL5 targets could reveal
that this E3 plays a role in regulating iron and/or oxygen homeostasis
independent of the IRP/IRE regulatory system.
While it has been clearly demonstrated that FBXL5 directly binds
iron, themechanismbywhich themetal gets loaded into the Hr domain
remains unknown. Somemetalloenzymes rely on chaperones for incor-
poration of the correct metal into their active site [81,82]. Recently,
PCBP1, has been identiﬁed as a putative chaperone that delivers iron
to both ferritin and the HIF hydroxylases [83,84]. It is plausible that
FBXL5 may also require an ancillary protein for insertion of iron into
its Hr domain. Another critical question is how FBXL5 is regulated in
an iron dependent manner via the UPS. Speciﬁcally, is there a dedicated
E3 ligase that tags the protein for proteasomal degradationwhen iron is
limiting and the FBXL5 degron is exposed?
The molecular details deﬁning the FBXL5-IRP substrate interactions
are also unresolved. Initial indications that IRP1, unlike IRP2, was not sub-
ject to iron-dependent degradation, focused attention on a 73 amino acid
insertion within IRP2 as a likely determinant for E3 ligase recognition
[85,86]. However, subsequent studies demonstrated that this region
was dispensable for IRP2 regulation [48,53,55]. More likely, IRP1 and
IRP2 share a common degron that can be selectively masked in a confor-
mation adopted by IRP1 following assembly of its Fe–S cluster. FBXL5 con-
tains six predicted leucine rich repeats [55], which are known to functionas substrate recognition motifs in other F-box proteins [87]. However,
which, if any of these repeats are required for FBXL5 substrate binding
is an open question. Intriguingly, iron bioavailability also appears to regu-
late the physical interaction between FBXL5 and IRP2 [55,56], suggesting
there may be additional iron-sensing mechanisms that control this E3 li-
gase subunit independent of its Hr domain.
Diverging from canonical Hr domains, the FBXL5 Hr does not ap-
pear to directly bind O2. Nevertheless, accumulation of FBXL5 and
its Hr domain in cells is regulated by oxygen availability via the
UPS. Delineation of the molecular mechanisms underlying FBXL5
oxygen-responsiveness, and its physiological relevance, may reveal
novel insights into the crosstalk between oxygen and iron homeosta-
sis. In addition to liver-speciﬁc FBXL5 ablation, mice lacking FBXL5 in
the intestine and brain will be pivotal in determining whether FBXL5
plays a role in iron absorption and neurodegeneration, respectively.
6. Conclusion
Multiple studies indicate that iron homeostasis is governed in part
through regulated proteolysis of ferroportin, HIF, IRPs, and FBXL5.
Iron binding to the FBXL5 Hr domain regulates its stability, which
has reciprocal affects on IRPs degradation. When bioavailable iron
levels are sufﬁcient for enzymatic activity, HIF Prolyl Hydroxylases
modify the transcription factor HIF, mediating its degradation.
When systemic demand for iron is attenuated, hepcidin expression
increases and it is released into the circulationwhere it binds ferroportin
to triggers its degradation. In an alternative cell autonomous pathway,
low cytosolic iron levels are directly sensed by ferroportin and result in
a conformational change promoting hepcidin-independent degradation
(Fig. 6).
While ferroportin, HIF, IRPs, and FBXL5 play critical roles in regu-
lating cellular and systemic iron homeostasis, it is becoming apparent
that there are multiple interconnections among the disparate path-
ways (Fig. 6). For example, HIF-2α contains an IRE in its 5′ UTR
[88]. Similar to the regulation of ferritin, IRP binding to its IRE under
conditions of iron deﬁciency inhibits HIF-2α translation, while
under iron replete conditions its expression is derepressed. HIF-2α
displays high expression levels in the kidney where it controls ex-
pression of erythropoietin, a hormone that stimulates the production
of erythrocytes [89]. The IRP/IRE regulatory system may temper red
blood cell production under conditions where iron is limiting to
downregulate the production of heme- and/or hemoglobin-deﬁcient
erythrocytes [88]. Ferroportin expression is also regulated posttran-
scriptionally via an IRE in its 5′ UTR. This phenotype is highlighted
in intestine speciﬁc Irp1−/−Irp2−/− mice. These mice, despite in-
creased hepcidin expression, display a paucity of bioavailable intesti-
nal iron levels in part due to the overexpression of ferroportin [90].
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Fig. 6. Interconnections in the proteolytic pathways responsible for maintaining iron
homeostasis. FBXL5 and HIF Prolyl Hydroxylases function as ostensible iron-sensors
and promote the degradation of IRPs and HIF, respectively. FBXL5 is degraded when
its Hr domain is prevented from binding iron. Ferroportin degradation is initiated
upon hepcidin binding or following low cytosolic iron availability. These diverse regu-
latory factors are intertwined at multiple levels including IRPs negatively regulating
HIF-α and ferroportin translation, and HIF-α inhibiting transcription of hepcidin.
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tion to maintain systemic iron homeostasis, may rely on proper IRP/
IRE regulation to protect themselves against excessive iron efﬂux
that could lead to iron deﬁciency [91]. As noted above, several HIF tar-
get genes, including hepcidin, are involved in maintaining iron ho-
meostasis. Interestingly, HIF is believed to transcriptionally repress
HAMP as loss of pVHL expression in the mouse liver stabilizes HIF-
α, attenuating hepcidin expression and stabilizing ferroportin [31].
This mechanism may be important for increasing iron levels in the
serum to facilitate erythropoiesis in response to physiological condi-
tions such as hypoxia. Additional studies are needed to advance our
understanding of the mechanisms regulating dynamic proteolysis in
iron metabolism. For example, degradation of the iron transport pro-
tein divalent metal transporter 1 has recently been suggested to be
regulated in an iron dependent manner [90,92,93]. Lastly, altered ex-
pression or activities of many of the regulatory factors discussed here
are frequently observed in human disease. Additional factors, such as
FBXL5, need to be analyzed in greater detail to determine whether
they contribute to iron related disorders or other diseases. Future
work has great potential to provide insights into disease etiology
and uncover new therapeutic targets for various pathologies.
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